Group 1 - The core viewpoint of the article is the strategic collaboration between Lao Bai Xing Pharmacy and Innovent Biologics to commercialize the innovative drug Masitide (Xin Er Mei) for metabolic disease management [1] - The partnership aims to integrate Innovent's core capabilities in innovative research and development with Lao Bai Xing's extensive retail network and professional service system to accelerate the nationwide distribution of Masitide [1] - Masitide is an innovative drug developed by Innovent Biologics for weight loss and blood sugar reduction, and Lao Bai Xing has over ten thousand stores covering major cities and county markets across the country [1] Group 2 - Both companies have reached a consensus on specific cooperation details, including supply chain assurance, patient service system development, and market promotion strategies [1] - The collaboration will utilize a comprehensive model of "store counters + pharmacist training + patient community operations" to establish a benchmark in metabolic disease management [1] - Innovent's founder emphasized that Lao Bai Xing's channel capabilities and professional services are crucial for reaching patients with Masitide, while Lao Bai Xing's founder highlighted the alignment of Masitide's clinical advantages with their chronic disease service system [1]

Core Viewpoint - Idorsia Ltd is proposing three candidates for election to its Board of Directors at the upcoming Annual General Meeting, aiming to enhance the Board's expertise in biopharmaceutical innovation and strategic execution [1][4][12]. Group 1: Board Composition - The nominees include Natalia Misciattelli and Gabriel Baertschi as independent members, and André C. Muller as a non-independent member [2][3]. - The proposed Board composition aims to strengthen the company with leaders who have extensive experience in global operations and biopharmaceutical innovation [3][4]. Group 2: Nominee Backgrounds - **Natalia Misciattelli**: CEO of AAVantgarde Bio with over 25 years of experience in biotechnology, focusing on therapeutic platforms and corporate development [5][6]. - **Gabriel Baertschi**: CEO of Grünenthal with more than 20 years in the pharmaceutical industry, known for his expertise in commercial strategy and market expansion [7][8]. - **André C. Muller**: Former CEO of Idorsia, instrumental in the company's development since its inception, bringing deep knowledge of Idorsia's business and strategy [9][10]. Group 3: Re-election of Current Board Members - The Board will also propose the re-election of Jean-Paul Clozel as Chairman, along with independent members Mathieu Simon and Sandy Mahatme, while Bart Filius will not stand for re-election [11][13]. Group 4: Annual General Meeting Details - The Annual General Meeting is scheduled for May 6, 2026, where shareholders are encouraged to register their shares by April 27, 2026, to participate in the voting process [14].

Core Viewpoint - Idorsia Ltd is proposing three candidates for election to its Board of Directors at the upcoming Annual General Meeting, aiming to enhance the Board's expertise in biopharmaceutical innovation and strategic execution [1][12]. Board Composition - The nominees include Natalia Misciattelli and Gabriel Baertschi as independent members, and André C. Muller as a non-independent member [2]. - The proposed Board composition aims to strengthen leadership with extensive experience in global operations and biopharmaceutical innovation, ensuring continuity through deep company knowledge [3]. Candidate Profiles - **Natalia Misciattelli**: CEO of AAVantgarde Bio with over 25 years of experience in biotechnology, focusing on therapeutic platforms and corporate development [5][6]. - **Gabriel Baertschi**: CEO of Grünenthal with more than 20 years in the pharmaceutical industry, known for his expertise in commercial strategy and market expansion [7][8]. - **André C. Muller**: Former CEO of Idorsia, who has been integral to the company's development since its inception, bringing extensive knowledge of Idorsia's business and strategic direction [9][10]. Re-election of Current Board Members - The Board will also propose the re-election of Jean-Paul Clozel as Chairman, along with independent members Mathieu Simon and Sandy Mahatme, while Bart Filius will not stand for re-election [11][13]. Annual General Meeting Details - The Annual General Meeting is scheduled for May 6, 2026, where shareholders are encouraged to register their shares by April 27, 2026, to participate in the voting process [14].

Sustainability Day March 24, 2026 Forward-Looking Statements Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to: | Forward-looking statements: | This presentation contains forward-looking statements regarding the Company's future plans, strategies, and pe ...

Core Viewpoint - NovaBay Pharmaceuticals, Inc. has announced a corporate name change to Stablecoin Development Corporation, indicating a strategic shift towards cryptocurrency [1][2] Group 1: Corporate Strategy - The company will adopt a new ticker symbol, SDEV, effective April 3 [2] - CEO Michael Kazley emphasized that the name change reflects the belief that stablecoins present a significant opportunity in digital finance [2] - The firm is transitioning from a pharmaceutical focus to becoming an "on-chain holding company," targeting long-term investments in protocol-level cryptocurrency ecosystems [2] Group 2: Market Performance - The Sky ecosystem operates with USDS, a yield-bearing, dollar-pegged stablecoin, and the SKY governance token [3] - At the time of reporting, the SKY token was priced at $0.07204, reflecting a 5.21% increase in the last 24 hours [3] - NovaBay shares experienced a 0.12% decline in after-hours trading after a significant 18.97% increase during regular trading [3] - Year-to-date, the stock has decreased by 95% [3] Group 3: Stock Analysis - NBY has shown weak price trends across short, medium, and long terms according to Benzinga's Edge Stock Rankings [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including over $438 million for investors in 2019, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was a "powerful support" for FDA approval, while the FDA had raised concerns about the clinical evidence [5]. - As a result of these misrepresentations, investors suffered damages when the true situation regarding the NDA was revealed [5].

Core Viewpoint - Robbins LLP is urging stockholders of Aquestive Therapeutics, Inc. to participate in a class action lawsuit due to alleged misleading information regarding the approval of the drug Anaphylm [1][2]. Group 1: Class Action Details - A class action was filed on behalf of investors who purchased or acquired Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026 [1]. - The allegations include that Aquestive misled investors about the approval timeline for Anaphylm, suggesting it was on track for approval by the January 31, 2026 PDUFA date, while the FDA had identified deficiencies preventing this [2][3]. Group 2: Impact on Stock Price - Following the announcement on January 9, 2026, regarding the FDA's letter identifying deficiencies, the stock price of Aquestive fell over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026 [3]. Group 3: Shareholder Actions - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by May 4, 2026, and can choose to remain absent class members if they do not wish to participate [4].

Core Viewpoint - Robbins LLP is urging stockholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who incurred losses to participate in a class action lawsuit due to alleged misleading information regarding the company's clinical trials and product safety [1][2]. Company Overview - Soleno Therapeutics is a pharmaceutical company focused on developing therapies for rare diseases, with its primary product being diazoxide choline extended-release tablets (DCCR) for treating hyperphagia in individuals with Prader-Willi syndrome (PWS) [1]. Class Action Details - A class action was filed for investors who purchased Soleno stock between March 26, 2025, and November 4, 2025 [2]. - Allegations include that Soleno misled investors about the safety and efficacy of DCCR, failing to disclose significant safety concerns related to fluid retention and other risks associated with the drug [2][3]. Stock Price Impact - Following the release of a report by Scorpion Capital on August 15, 2025, which detailed issues with Soleno's clinical trials, the stock price dropped nearly 12% over two trading days [3]. - After a patient death was reported on September 10, 2025, the stock declined nearly 19% over two trading days [4]. - On November 4, 2025, after reporting third-quarter financial results, the stock price fell from approximately $64 to about $47 per share, marking a one-day decline of approximately 27% [5]. Shareholder Actions - Shareholders interested in serving as lead plaintiffs must submit their papers by May 5, 2026, although participation in the case is not required to be eligible for recovery [6].

Core Viewpoint - Sol-Gel Technologies Ltd. has announced an underwritten offering of 459,112 ordinary shares at a price of $72.00 per share, aiming to raise approximately $33.1 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering is expected to close on or about March 25, 2026, subject to customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as Great Point Partners, LLC, Trails Edge Capital Partners, and others [2]. - TD Cowen and LifeSci Capital are acting as joint book-running managers for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the continued development of SGT-610, including pre-commercialization activities and research and development, with the remainder allocated for working capital and general corporate purposes [3]. Group 3: Company Overview - Sol-Gel Technologies is a specialized dermatology company focused on innovative therapies for rare and serious skin diseases, with its lead candidate SGT-610 being developed for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome [7]. - SGT-610 is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor, which may offer an improved safety profile compared to oral hedgehog inhibitors [7]. - The company is also advancing SGT-210, an investigational topical EGFR inhibitor, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY® [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Background - The lawsuit alleges that Ultragenyx provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5] - It is claimed that the defendants made overly positive statements while concealing material adverse facts about setrusumab's effectiveness, leading to artificially inflated stock prices [6]